Published Date: 16 Feb 2023
According to a report by the Alzheimer's Association task force, it's time to reframe what "clinically meaningful" means and change expectations about clinical trials.
Read Full NewsA dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.
In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.
1.
Global inequalities found in cancer research funding
2.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
3.
Review looks at potential treatment targets in the tumor microenvironment.
4.
Accurately identified high-grade prostate cancer through urine testing.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in ACS Post-PCI: ULTIMATE-DAPT Trial
2.
AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency
3.
Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics
4.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
5.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A New Era in Managing Cancer-Associated Thrombosis
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
Efficient Management of First line ALK-rearranged NSCLC - Part III
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation